Movement Alert｜Genscript Biotech Rises 5.04% in Regular Trading, CXO Sector Interim Results Beat Expectations Driving Sector Momentum

Market Focus07-15 11:22

On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window, where multiple brokerages noted that the digestion of earlier low-price orders has confirmed a dual inflection point in both revenue and profit for the industry, further strengthening the valuation recovery thesis.

Data from 22 listed CXO companies showed first-quarter revenue and net profit grew 18.6% and 21.9% year-over-year respectively, with domestic CXO firms reporting ample orders and improving volume-price dynamics. As the global leader in gene synthesis and a core CRDMO platform for biologics, Genscript benefits from the broader industry recovery and expanding AI-driven drug discovery demand.

Within the Life Sciences Tools and Services sector, peers also posted strong gains, with JOINN up 17.66%, Insilico up 10.64%, Pharmaron up 9.24%, WuXi AppTec up 5.19%, and WuXi Biologics up 4.61%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100407286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100407286","market":"us","top_or_hot":-1,"title":"Movement Alert｜Genscript Biotech Rises 5.04% in Regular Trading, CXO Sector Interim Results Beat Expectations Driving Sector Momentum","media":"Market Focus","content":"<p><p>On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window, where multiple brokerages noted that the digestion of earlier low-price orders has confirmed a dual inflection point in both revenue and profit for the industry, further strengthening the valuation recovery thesis.</p><p>Data from 22 listed CXO companies showed first-quarter revenue and net profit grew 18.6% and 21.9% year-over-year respectively, with domestic CXO firms reporting ample orders and improving volume-price dynamics. As the global leader in gene synthesis and a core CRDMO platform for biologics, Genscript benefits from the broader industry recovery and expanding AI-driven drug discovery demand.</p><p>Within the Life Sciences Tools and Services sector, peers also posted strong gains, with JOINN up 17.66%, Insilico up 10.64%, Pharmaron up 9.24%, WuXi AppTec up 5.19%, and WuXi Biologics up 4.61%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Genscript Biotech Rises 5.04% in Regular Trading, CXO Sector Interim Results Beat Expectations Driving Sector Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Genscript Biotech Rises 5.04% in Regular Trading, CXO Sector Interim Results Beat Expectations Driving Sector Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window, where multiple brokerages noted that the digestion of earlier low-price orders has confirmed a dual inflection point in both revenue and profit for the industry, further strengthening the valuation recovery thesis.</p><p>Data from 22 listed CXO companies showed first-quarter revenue and net profit grew 18.6% and 21.9% year-over-year respectively, with domestic CXO firms reporting ample orders and improving volume-price dynamics. As the global leader in gene synthesis and a core CRDMO platform for biologics, Genscript benefits from the broader industry recovery and expanding AI-driven drug discovery demand.</p><p>Within the Life Sciences Tools and Services sector, peers also posted strong gains, with JOINN up 17.66%, Insilico up 10.64%, Pharmaron up 9.24%, WuXi AppTec up 5.19%, and WuXi Biologics up 4.61%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1100407286","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100407286","pubTimestamp":1784085738,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨5.04%，CXO板块中期业绩超预期，推动板块动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On July 15, Genscript Biotech rose 5.04% in regular trading, trading at HK$15.0 per share, with turnover of HK$206 million. The rally was driven by the ongoing CXO sector interim results window, where multiple brokerages noted that the digestion of earlier low-price orders has confirmed a dual inflection point in both revenue and profit for the industry, further strengthening the valuation recovery thesis.Data from 22 listed CXO companies showed first-quarter revenue and net profit grew 18.6% and 21.9% year-over-year respectively, with domestic CXO firms reporting ample orders and improving volume-price dynamics. As the global leader in gene synthesis and a core CRDMO platform for biologics, Genscript benefits from the broader industry recovery and expanding AI-driven drug discovery demand.Within the Life Sciences Tools and Services sector, peers also posted strong gains, with JOINN up 17.66%, Insilico up 10.64%, Pharmaron up 9.24%, WuXi AppTec up 5.19%, and WuXi Biologics up 4.61%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100407286","isCrawlerRequest":true}